Mycobacterial cell wall synthesis inhibitor

0 marketed 2 in Phase 3

This page covers all Mycobacterial cell wall synthesis inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DprE1 (decaprenylphosphoryl-arabinose-1-phosphatase), DprE1 (decaprenylphosphoryl-β-D-ribose 2'-epimerase).

Targets

DprE1 (decaprenylphosphoryl-arabinose-1-phosphatase) · DprE1 (decaprenylphosphoryl-β-D-ribose 2'-epimerase)

Phase 3 pipeline (2)

Delamanid in Oral Dosage Form · Wits Health Consortium (Pty) Ltd · Infectious Disease
Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.
Delamanid (DLM) · Wuhan Pulmonary Hospital · Infectious Disease
Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.